Abstract Background: Klebsiella species are the second most common uropathogen after Escherichia coli . We attempted to estimate the proportion of Klebsiella species as an uropathogen among inpatients and to determine their antimicrobial susceptibility pattern. Methods: This hospital-based cross-sectional study was conducted among 7057 urine samples received from the patients admitted in different wards of our teaching hospital during May 2022–April 2024. Urine samples were processed aerobically in Cysteine Lactose Electrolyte Deficient media at 37°C. Bacterial colonies were identified by colony morphology, Gram’s staining and conventional biochemical tests. Antimicrobial susceptibility tests were performed for Klebsiella -positive colonies on Mueller–Hinton Agar using the Kirby–Bauer disc diffusion method. Results: Out of 7057 urine samples, 1050 (14.8%) showed significant growth. Klebsiella species constituted 370 (35.2%) of these. Of these, 54.8% showed resistance to nitrofurantoin, 45.7% to ciprofloxacin, 42.1% to levofloxacin, 33.2% to piperacillin and tazobactam combination, 32% to amikacin and 21.6% to meropenem. However, no resistance was observed against colistin and tigecycline. Conclusions: Our observations suggest that, ciprofloxacin and levofloxacin should be recommended as the first-line drugs, keeping amikacin and meropenem as reserve drugs for treating urinary tract infections in this setting.
Debbarma et al. (Thu,) studied this question.